Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cytek Biosciences Inc CTKB

Technology Scientific & Technical Instruments
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion... see more

Recent & Breaking News (NDAQ:CTKB)

Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire November 20, 2024

Cytek® Biosciences Named "Overall BioTech Company of the Year" in 2024 BioTech Breakthrough Awards Program

GlobeNewswire November 19, 2024

Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter

GlobeNewswire November 7, 2024

Cytek Biosciences Reports Third Quarter 2024 Financial Results

GlobeNewswire November 5, 2024

Cytek Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire October 30, 2024

Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024

GlobeNewswire October 29, 2024

Cytek® Biosciences Brings Full Spectrum Profiling(TM) (FSP(TM)) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe

GlobeNewswire September 18, 2024

Cytek Announces Resignation of Chief Operating Officer Chris Williams

GlobeNewswire September 12, 2024

Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility

GlobeNewswire August 21, 2024

Cytek Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire August 8, 2024

Cytek Biosciences Reports Second Quarter 2024 Financial Results

GlobeNewswire August 6, 2024

Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm

GlobeNewswire July 30, 2024

Cytek Biosciences to Report Second Quarter 2024 Financial Results on August 6, 2024

GlobeNewswire July 30, 2024

Cytek Biosciences Announces $50 Million Stock Repurchase Program

GlobeNewswire June 6, 2024

Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire May 30, 2024

1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China

GlobeNewswire May 28, 2024

Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems

GlobeNewswire May 20, 2024

Cytek Biosciences Reports First Quarter 2024 Financial Results

GlobeNewswire May 8, 2024

Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe

GlobeNewswire April 30, 2024

Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024

GlobeNewswire April 29, 2024